-transparent.png){kind=logo}
Antiarrhythmic treatment was required in 35 patients aged one day to 11 8/12 years (average 5 7/12 years) for one or several of the following arrhythmias: paroxysmal supraventricular tachycardia (17), ventricular extrasystole (16), ventricular tachycardia (17), ventricular extrasystole (16), ventricular tachycardia (4), junctional tachycardia (4), and atrial flutter (3). 300 mg/m2/day oral propafenone was administered in 3 to 4 divided doses. The arrhythmia in 21 of the 35 patients had been unsuccessfully treated by digoxin (6), verapamil (5), ajmalin (4), propranolol (3), spartein (1), phenytoin (1), and lidocain (1) prior to the propafenone therapy. However, the arrhythmias could be abolished or reduced in 30 patients (85.7%) by Propafenone. In 5 patients with supraventricular tachycardia (2), junctional tachycardia (2), or ventricular extrasystole (1), propafenone therapy had no effect. In two other patients propafenone led to atrioventricular conduction disturbances and had to be discontinued. Propafenone is an effective well tolerated antiarrhythmic drug without major side effects in pediatric patients.
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
August 1993,
The American journal of cardiology,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
January 1990,
The Turkish journal of pediatrics,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
December 1969,
Medizinische Klinik,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
January 2012,
Kardiologiia,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
September 1984,
Canadian Medical Association journal,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
August 1986,
La Clinica terapeutica,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
May 1998,
The American journal of cardiology,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
January 1984,
Arzneimittel-Forschung,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
January 1981,
Paediatrician,
F Dressler, and
L Grävinghoff, and
E Grütte, and
B K Jüngst, and
R Liersch, and
H Nomayo, and
I Puls, and
H W Rautenburg, and
A Schmaltz, and
G Schumacher
January 1995,
Drug safety,
